文献速递肿瘤 PET/CT核素与放射性配体治疗

试点可行性研究:18F-DPA-714 PET/CT 巨噬细胞显像在三阴性乳腺癌中的应用(EITHICS)

Pilot Feasibility Study: 18 F-DPA-714 PET/CT Macrophage Imaging in Triple-Negative Breast Cancers (EITHICS).
PubMed 文献 · Clin Nucl Med · 2024-06-20

这项前瞻性试点研究纳入13例三阴性乳腺癌患者,评估18F-DPA-714 TSPO PET/CT显像与免疫组化、放射自显影及TSPO基因多态性的关系。结果显示肿瘤靶向良好、TBR优异,并识别出三种摄取模式,可能受TSPO多态性状态影响。作者认为需在更大规模人群中进一步研究该新型生物标志物的预后价值。

要点

  • 11/13(84%)的三阴性乳腺癌肿瘤以M2极化巨噬细胞为主,中位比例为82%(范围44%-94%)。
  • 18F-DPA-714 PET/CT可清晰识别三阴性乳腺癌肿瘤,肿瘤与本底比值优异。
  • 作者认为需在更大规模人群中进一步研究该新型生物标志物的预后价值。

核心结论

  • 本研究成功证明18F-DPA-714可靶向三阴性乳腺癌肿瘤,肿瘤与本底比值优异,并可分层出三种摄取模式,可能受TSPO多态性状态影响。
  • 作者认为需在更大规模人群中进一步研究该新型生物标志物的预后价值。

研究设计与样本

  • 前瞻性试点研究(EITHICS,NCT04320030),纳入13例三阴性乳腺癌患者。
  • 患者接受TSPO基因分型(HAB、MAB、LAB)、18F-FDG PET/CT和乳腺MRI检查。
  • 计算半定量PET参数,在肿瘤病灶、健康乳腺组织和胸肌上定义VOI,获得SUV、肿瘤与本底比值(TBR)和时间-放射性曲线(TAC)。
  • 另进行免疫组化、3H-DPA-714和3H-PK-11195放射自显影。

主要发现

  • 多数三阴性乳腺癌肿瘤(11/13,84%)以M2极化巨噬细胞为主,中位比例为82%(范围44%-94%)。
  • 18F-DPA-714 PET/CT可清晰识别三阴性乳腺癌肿瘤,肿瘤与本底比值优异。
  • 参照肌肉本底,识别出三种18F-DPA-714 TAC模式:「高于肌肉」「等于肌肉」「低于肌肉」。
  • 「高于肌肉」组(2例HAB和2例MAB)肿瘤TAC的18F-DPA-714蓄积斜率为1.35,SUVmean中位数为4.02(2.09-5.31)。
  • 「等于肌肉」组(3例HAB、3例MAB和1例LAB)蓄积斜率为0.62,SUVmean中位数为1.66(0.93-3.07);「低于肌肉」组(1例LAB和1例MAB)蓄积斜率为0.22,SUVmean中位数为0.61(0.43-1.02)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者认为需在更大规模人群中进一步研究,以评估该新型生物标志物的预后价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ABSTRACT: Tumor-associated macrophages are targets of interest in triple-negative breast cancer (TNBC). The translocator protein 18 kDa (TSPO) is a sensitive marker for macrophages and holds potential relevance in TNBC stratification. This pilot prospective study (EITHICS, NCT04320030) aimed to assess the potential of TSPO PET/CT imaging using 18 F-DPA-714 in primary TNBC, compared with immunohistochemistry, autoradiography, and TSPO polymorphism. PATIENTS AND METHODS: Thirteen TNBC patients were included. They underwent TSPO genotyping (HAB, MAB, LAB), 18 F-FDG PET/CT, and breast MRI. Semiquantitative PET parameters were computed. VOIs were defined on the tumor lesion, healthy breast tissue, and pectoral muscle to obtain SUV, tumor-to-background ratio (TBR), and time-activity curves (TACs). Additionally, immunohistochemistry, 3 H-DPA-714, and 3 H-PK-11195 autoradiography were conducted. RESULTS: The majority of TNBC tumors (11/13, 84%) had a preponderance of M2-polarized macrophages with a median proportion of 82% (range, 44%-94%). 18 F-DPA-714 PET/CT clearly identified TNBC tumors with an excellent TBR. Three distinct patterns of 18 F-DPA-714 TACs were identified, categorized as "above muscular," "equal to muscular," and "below muscular" with reference to the muscular background. For the "above muscular" group (2 HAB and 2 MAB), "equal muscular" group (3 HAB, 3 MAB, and 1 LAB), and "below muscular" group (1 LAB and 1 MAB), tumor TACs showed a 18 F-DPA-714 accumulation slope of 1.35, 0.62, and 0.22, respectively, and a median SUV mean of 4.02 (2.09-5.31), 1.66 (0.93-3.07), and 0.61 (0.43-1.02). CONCLUSIONS: This study successfully demonstrated TNBC tumor targeting by 18 F-DPA-714 with an excellent TBR, allowing to stratify 3 patterns of uptake potentially influenced by the TSPO polymorphism status. Further studies in larger populations should be performed to evaluate the prognostic value of this new biomarker.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Rousseau C, Metz R, Kerdraon O, et al. Pilot Feasibility Study: 18 F-DPA-714 PET/CT Macrophage Imaging in Triple-Negative Breast Cancers (EITHICS). Clin Nucl Med. 2024. PMID: 38913962. doi:10.1097/RLU.0000000000005338

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。